Overview

DPX-Survivac, Alone or in Combination With Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status:
Recruiting

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac alone or in combination with pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

Phase:

Phase 2

Details

Lead Sponsor:

ImmunoVaccine Technologies, Inc. (IMV Inc.)

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Cyclophosphamide
Pembrolizumab